Patents by Inventor Douglas A. Lorenz

Douglas A. Lorenz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
    Patent number: 7115279
    Abstract: A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: October 3, 2006
    Inventors: William J. Curatolo, Dwayne T. Friesen, Michael J. Gumkowski, Douglas A. Lorenz, James A. S. Nightingale, Roger B. Ruggeri, Ravi M. Shanker
  • Dosage forms comprising a CETP inhibitors and an HMG-CoA reductase inhibitor
    Publication number: 20040197398
    Abstract: A dosage form comprises (1) a solid amorphous dispersion comprising a cholesterol ester transfer protein inhibitor and an acidic concentration-enhancing polymer and (2) an HMG-CoA reductase inhibitor. The solid amorphous dispersion and the HMG-CoA reductase inhibitor are combined in the dosage form so that the solid amorphous dispersion and the HMG-CoA reductase inhibitor are substantially separate from one another in the dosage form.
    Type: Application
    Filed: December 18, 2003
    Publication date: October 7, 2004
    Applicant: Pfizer Inc.
    Inventors: Dwayne T. Friesen, David K. Lyon, Douglas A. Lorenz, Bruno C. Hancock, Timothy J. McDermott, Ravi M. Shanker
  • Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
    Publication number: 20040185102
    Abstract: A dosage form comprises (1) a solid amorphous dispersion comprising a cholesteryl ester transfer protein inhibitor and a neutral or neutralized acidic polymer and (2) an HMG-CoA reductase inhibitor. The dosage form provides improved chemical stability of the HMG-CoA reductase inhibitor.
    Type: Application
    Filed: December 18, 2003
    Publication date: September 23, 2004
    Applicant: Pfizer Inc
    Inventors: Dwayne T. Friesen, David K. Lyon, Douglas A. Lorenz, Rodney J. Ketner, Bruno C. Hancock, Timothy J. McDermott, Ravi M. Shanker
  • Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
    Publication number: 20030186952
    Abstract: A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.
    Type: Application
    Filed: February 1, 2002
    Publication date: October 2, 2003
    Inventors: Marshall D. Crew, William J. Curatolo, Dwayne T. Friesen, Michael Jon Gumkowski, Douglas A. Lorenz, James A. S. Nightingale, Roger B. Ruggeri, Ravi M. Shanker
  • Pharmaceutical compositions of dispersions of drugs and neutral polymers
    Publication number: 20030091643
    Abstract: In one aspect, pharmaceutical compositions comprising dispersions of an acid-sensitive drug and a neutral dispersion polymer are disclosed. The acid-sensitive drug has improved chemical stability relative to dispersions of the drug and acidic polymers. In another aspect, pharmaceutical compositions of low-solubility drugs and amphiphilic, hydroxy-functional vinyl copolymers are disclosed.
    Type: Application
    Filed: June 18, 2002
    Publication date: May 15, 2003
    Inventors: Dwayne T. Friesen, Michael J. Gumkowski, Rodney J. Ketner, Douglas A. Lorenz, James A. S. Nightingale, Ravi M. Shanker, James B. West
  • Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
    Publication number: 20020103225
    Abstract: A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.
    Type: Application
    Filed: July 30, 2001
    Publication date: August 1, 2002
    Inventors: William J. Curatolo, Dwayne T. Friesen, Michael J. Gumkowski, Douglas A. Lorenz, James A. S. Nightingale, Roger B. Ruggeri, Ravi M. Shanker
  • Pharmaceutical compositions providing enhanced drug concentrations
    Publication number: 20020006443
    Abstract: A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.
    Type: Application
    Filed: December 20, 2000
    Publication date: January 17, 2002
    Inventors: William J. Curatolo, Ravi M. Shanker, walter C. Babcock, Dwayne T. Friesen, James A.S. Nightingale, Douglas A. Lorenz
  • Pharmaceutical compositions of glycogen phosphorylase inhibitors
    Publication number: 20010053778
    Abstract: Pharmaceutical compositions comprise a glycogen phosphorylase inhibitor and at least one concentration-enhancing polymer. The composition may be a simple physical mixture of glycogen phosphorylase inhibitor and concentration-enhancing polymer or a dispersion of glycogen phosphorylase inhibitor and polymer.
    Type: Application
    Filed: March 14, 2001
    Publication date: December 20, 2001
    Inventors: Dennis J. Hoover, Ravi M. Shanker, James A.S. Nightingale, Dwayne T. Friesen, Douglas A. Lorenz
  • Glycogen phosphorylase inhibitor
    Publication number: 20010053791
    Abstract: Pharmaceutical compositions of a particularly effective sparingly soluble glycogen phosphorylase inhibitor are disclosed, as well as methods of making such compositions and dosage forms from such compositions.
    Type: Application
    Filed: March 14, 2001
    Publication date: December 20, 2001
    Inventors: Walter C. Babcock, Marshall D. Crew, Dwayne T. Friesen, Bruno C. Hancock, Douglas A. Lorenz, Chris Macri, James A.S. Nightingale, Ravi M. Shanker
  • Enantiomeric resolution of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone
    Patent number: 5288916
    Abstract: There is disclosed a method of separating enantiomers of 4-(3',4'-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone comprising contacting the same with a homogeneous or nonhomogeneous liquid mixture of solvent and water, the mixture containing substantially pure and unsupported gamma-cyclodextrin or its derivatives. Also disclosed are methods of further enantiomerically enriching solid mixtures obtained from the enantiomer separation method and further extracting one enantiomer by solvent extraction of the solid mixtures obtained.
    Type: Grant
    Filed: March 25, 1993
    Date of Patent: February 22, 1994
    Assignee: Bend Research, Inc.
    Inventors: Douglas A. Lorenz, Daniel J. Brose